Senseonics Holdings Inc (SENS)

NASD · Healthcare · Medical Devices · USA

Senseonics Holdings Inc is a small cap company (market value between $300 million and $2 billion) in the Medical Devices industry.

Senseonics Holdings develops and commercializes implantable continuous glucose monitoring systems for people with diabetes. Its Eversense devices measure glucose levels under the skin for up to twelve months using a removable smart transmitter and app, compared to seven to fifteen days for conventional systems. The company markets these products in the United States and European markets.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Senseonics Holdings Inc stock.

Our verdict on SENS

Overvalued: intrinsic value $1.11 per share, market price $10.16, margin of safety -815.1% (as of 2026-11-17).

A 0.9x revenue multiple, discounted for its losses, values the shares at $1.11; the price of $10.16 is 815% above that value.

ETFs with the most weight in SENS

16 more funds hold it; the full list is part of the paid plan.

More on SENS

Browse

Peers in Medical Devices

All 140 Medical Devices stocks

Cheaper than SENS in Medical Devices

55 more in this industry show a wider margin of safety.

Is SENS undervalued or overvalued?

SENS is overvalued (as of the 2026-11-17 close). A 0.9x revenue multiple, discounted for its losses, values the shares at $1.11; the price of $10.16 is 815% above that value.

What is the intrinsic value of SENS?

$1.11 per share (as of the 2026-11-17 close), against a market price of $10.16. That is a margin of safety of -815.1%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.